229 related articles for article (PubMed ID: 10868516)
21. Novel thrombolytic agents.
Verstraete M; Lijnen HR
Cardiovasc Drugs Ther; 1994 Dec; 8(6):801-11. PubMed ID: 7742258
[TBL] [Abstract][Full Text] [Related]
22. Fibrinolytic agents: mechanisms of activity and pharmacology.
Lijnen HR; Collen D
Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and clinical impact of the unique molecular structure of a new plasminogen activator.
Smalling RW
Eur Heart J; 1997 Dec; 18 Suppl F():F11-6. PubMed ID: 9447335
[TBL] [Abstract][Full Text] [Related]
24. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
25. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
26. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
27. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): a thrombolytic drug optimized by natural selection.
Schleuning WD
Haemostasis; 2001; 31(3-6):118-22. PubMed ID: 11910176
[TBL] [Abstract][Full Text] [Related]
28. Towards the development of improved thrombolytic agents.
Lijnen HR; Collen D
Br J Haematol; 1991 Mar; 77(3):261-6. PubMed ID: 1901494
[No Abstract] [Full Text] [Related]
29. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
30. The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
Gardell SJ
Toxicol Pathol; 1993; 21(2):190-8. PubMed ID: 8210941
[TBL] [Abstract][Full Text] [Related]
31. [Staphylokinase for a better thrombolytic treatment of heart and platelet diseases].
Vanderschueren S
Verh K Acad Geneeskd Belg; 2000; 62(1):69-75. PubMed ID: 10769618
[TBL] [Abstract][Full Text] [Related]
32. New developments in thrombolytic therapy.
Collen D; Gold HK
Verh K Acad Geneeskd Belg; 1989; 51(3):191-228; discussion 229. PubMed ID: 2686261
[TBL] [Abstract][Full Text] [Related]
33. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
34. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
[TBL] [Abstract][Full Text] [Related]
35. [Increased efficacy of thrombolytic therapy in acute myocardial infarction by improved properties of new thrombolytic agents].
Huber K
Wien Klin Wochenschr; 2000 Sep; 112(17):742-8. PubMed ID: 11042902
[TBL] [Abstract][Full Text] [Related]
36. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
37. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
Ferres H
Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
[TBL] [Abstract][Full Text] [Related]
38. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
[TBL] [Abstract][Full Text] [Related]
39. [The fibrinolytic system and its activators].
Seifried E
Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
[TBL] [Abstract][Full Text] [Related]
40. [Thrombolytic therapy].
Matsuda T
Nihon Rinsho; 1998 Oct; 56(10):2577-81. PubMed ID: 9796322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
